Naciri Meryem, Aouzah Fatima Ezzahra, El Ghanmi Adil, Ghazi Bouchra, Fichtali Karima, Mohammed Sqalli Houssaini, Kouhen Fadila
Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Rabat 10100, Morocco.
Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Casablanca 20230, Morocco.
Ecancermedicalscience. 2025 Jul 2;19:1939. doi: 10.3332/ecancer.2025.1939. eCollection 2025.
Mutations in the BRCA1 and BRCA2 genes significantly increase the risk of hereditary cancers, mainly of the breast and ovary, but also of other cancers such as those of the pancreas, prostate and cervix. In carriers of these mutations, multiple primary malignancies (MPM) represent a complex clinical challenge, influenced by genetic and environmental factors, as well as previous cancer treatments. The case reports a patient with a BRCA1 mutation with a family history of breast and ovarian cancer and who developed cervical cancer then recurrent triple-negative breast cancer treated with mastectomy, radiotherapy, chemotherapy and Poly (Adenosine diphosohate-ribose) polymérase inhibitors. This case underlines the interplay between different malignancies in the context of breast cancer mutations and the importance of specific and personalised treatment of patients with multiple primary malignancies.
BRCA1和BRCA2基因的突变显著增加遗传性癌症的风险，主要是乳腺癌和卵巢癌，也包括其他癌症，如胰腺癌、前列腺癌和宫颈癌。在这些突变携带者中，多发性原发性恶性肿瘤（MPM）是一个复杂的临床挑战，受到遗传和环境因素以及既往癌症治疗的影响。该病例报告了一名携带BRCA1突变且有乳腺癌和卵巢癌家族史的患者，其患宫颈癌后又复发三阴性乳腺癌，接受了乳房切除术、放疗、化疗和聚（二磷酸腺苷核糖）聚合酶抑制剂治疗。该病例强调了在乳腺癌突变背景下不同恶性肿瘤之间的相互作用，以及对多发性原发性恶性肿瘤患者进行特异性和个性化治疗的重要性。
